<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - 獲取免費報告) 的股價在週三達到了新的 52 周高點。該股最高交易價格為 41.05 美元，最後交易價格為 40.9750 美元，成交量為 250063 股。該股此前收盤價為 40.97 美元。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
<p>APLS 已經成為多份研究分析師報告的主題。Roth Mkm 在 4 月 2 日的研究報告中將 Apellis Pharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。花旗集團在 4 月 1 日的報告中重申了 “中性” 評級，並將 Apellis Pharmaceuticals 的目標價設定為 41.00 美元（下調自 44.00 美元）。Wedbush 在 2 月 25 日的報告中將 Apellis Pharmaceuticals 的目標價從 20.00 美元下調至 18.00 美元，並對該股給予 “中性” 評級。HC Wainwright 在 4 月 1 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”，並將該公司的目標價從 48.00 美元下調至 41.00 美元。最後，Needham &amp; Company LLC 在 3 月 31 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。三位投資分析師對該股給予 “買入” 評級，十八位分析師給予 “持有” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Apellis Pharmaceuticals 的共識評級為 “持有”，共識目標價為 34.89 美元。</p>
<p><strong>查看我們關於 Apellis Pharmaceuticals 的最新報告</strong></p>
<h2>Apellis Pharmaceuticals 股票上漲 0.0%</h2>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p>該公司的 50 日簡單移動平均線為 29.59 美元，200 日簡單移動平均線為 25.35 美元。該公司的債務與股本比率為 0.98，流動比率為 3.14，速動比率為 2.70。該公司的市值為 52.5 億美元，市盈率為 315.29，貝塔值為-0.24。</p>
<p>Apellis Pharmaceuticals (NASDAQ:APLS - 獲取免費報告) 最近於 2 月 24 日發佈了季度財報。該公司報告每股收益（EPS）為 0.47 美元，超出市場共識預期的（-0.39 美元）0.86 美元。Apellis Pharmaceuticals 的淨利潤率為 2.23%，股本回報率為 8.20%。該公司本季度的收入為 1.9991 億美元，而分析師預期為 1.9928 億美元。在去年同期，該公司每股收益為（-0.29 美元）。該公司的季度收入同比下降了 5.9%。分析師平均預測 Apellis Pharmaceuticals, Inc.在本年度將發佈-1.23 的每股收益。</p>
<h2>機構投資者對 Apellis Pharmaceuticals 的看法</h2>
<p>大型投資者最近對該股的持倉進行了調整。SG Americas Securities LLC 在第四季度將其在 Apellis Pharmaceuticals 的持倉增加了 35.9%。SG Americas Securities LLC 現在擁有 567,046 股該公司的股票，價值 14,244,000 美元，在上個季度購買了 149,654 股。EFG Asset Management North America Corp.在第三季度將其在 Apellis Pharmaceuticals 的持倉增加了 48.0%。EFG Asset Management North America Corp.現在擁有 155,399 股該公司的股票，價值 3,517,000 美元，在上個季度購買了 50,375 股。HighVista Strategies LLC 在第三季度將其在 Apellis Pharmaceuticals 的持倉增加了 68.2%。HighVista Strategies LLC 現在擁有 145,729 股該公司的股票，價值 3,298,000 美元，在上個季度購買了 59,066 股。Readystate Asset Management LP 在第三季度購買了 Apellis Pharmaceuticals 的新股份，價值 5,476,000 美元。最後，諾瓦斯科舍銀行在第三季度將其在 Apellis Pharmaceuticals 的持倉增加了 144.8%。諾瓦斯科舍銀行現在擁有 1,456,225 股該公司的股票，價值 32,954,000 美元，在上個季度購買了 861,413 股。96.29% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Apellis Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Apellis Pharmaceuticals, Inc.，在 NASDAQ 交易，股票代碼為 APLS，是一家臨牀階段的生物製藥公司，專注於開發針對補體級聯反應的新療法，以治療罕見且嚴重的疾病。該公司的研發工作集中在調節補體蛋白，以應對一系列眼科、血液和腎臟疾病。Apellis 利用其專有的 compstatin 技術平台設計針對性抑制劑，旨在改善患者的治療效果和生活質量。</p>
<p>該公司的主要上市產品 Syfovre（pegcetacoplan）是一種用於治療與年齡相關的黃斑變性引起的地理萎縮的玻璃體內補體 C3 抑制劑，並正在對其他視網膜疾病進行持續研究。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Apellis Pharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Apellis Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Apellis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Apellis Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

APLS

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

<p>Apellis Pharmaceuticals（納斯達克代碼：APLS）創下了 52 周新高，達到 41.05 美元，收盤價為 40.9750 美元，交易量為 250,063 股。分析師的評級意見不一，其中三位給予買入評級，十八位給予持有評級，二位給予賣出評級。該公司報告每股收益為 0.47 美元，超出預期，但收入同比下降了 5.9%。機構投資者持有 96.29% 的股份，Apellis 專注於罕見疾病的治療，其主要產品 Syfovre 已獲批准用於治療地理性萎縮</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report)'s share price reached a new 52-week high on Wednesday . The stock traded as high as $41.05 and last traded at $40.9750, with a volume of 250063 shares trading hands. The stock had previously closed at $40.97.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - 獲取免費報告) 的股價在週三達到了新的 52 周高點。該股最高交易價格為 41.05 美元，最後交易價格為 40.9750 美元，成交量為 250063 股。該股此前收盤價為 40.97 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
</div><p>APLS has been the subject of several research analyst reports. Roth Mkm downgraded shares of Apellis Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, April 2nd. Citigroup reissued a &#34;neutral&#34; rating and set a $41.00 price objective (down from $44.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Wedbush cut their price objective on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a &#34;neutral&#34; rating on the stock in a report on Wednesday, February 25th. HC Wainwright lowered shares of Apellis Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price objective for the company from $48.00 to $41.00 in a report on Wednesday, April 1st. Finally, Needham &amp; Company LLC lowered shares of Apellis Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of &#34;Hold&#34; and a consensus price target of $34.89.</p>
<div class="lb-trans"><p>APLS 已經成為多份研究分析師報告的主題。Roth Mkm 在 4 月 2 日的研究報告中將 Apellis Pharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。花旗集團在 4 月 1 日的報告中重申了 “中性” 評級，並將 Apellis Pharmaceuticals 的目標價設定為 41.00 美元（下調自 44.00 美元）。Wedbush 在 2 月 25 日的報告中將 Apellis Pharmaceuticals 的目標價從 20.00 美元下調至 18.00 美元，並對該股給予 “中性” 評級。HC Wainwright 在 4 月 1 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”，並將該公司的目標價從 48.00 美元下調至 41.00 美元。最後，Needham &amp; Company LLC 在 3 月 31 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。三位投資分析師對該股給予 “買入” 評級，十八位分析師給予 “持有” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Apellis Pharmaceuticals 的共識評級為 “持有”，共識目標價為 34.89 美元。</p>
</div><p><strong>Check Out Our Latest Report on Apellis Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Apellis Pharmaceuticals 的最新報告</strong></p>
</div><h2>Apellis Pharmaceuticals Stock Up 0.0%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票上漲 0.0%</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p>The company's fifty day simple moving average is $29.59 and its 200-day simple moving average is $25.35. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70. The firm has a market capitalization of $5.25 billion, a PE ratio of 315.29 and a beta of -0.24.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 29.59 美元，200 日簡單移動平均線為 25.35 美元。該公司的債務與股本比率為 0.98，流動比率為 3.14，速動比率為 2.70。該公司的市值為 52.5 億美元，市盈率為 315.29，貝塔值為-0.24。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The business had revenue of $199.91 million for the quarter, compared to analyst estimates of $199.28 million. During the same period in the previous year, the company earned ($0.29) earnings per share. The business's revenue for the quarter was down 5.9% on a year-over-year basis. On average, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.23 EPS for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals (NASDAQ:APLS - 獲取免費報告) 最近於 2 月 24 日發佈了季度財報。該公司報告每股收益（EPS）為 0.47 美元，超出市場共識預期的（-0.39 美元）0.86 美元。Apellis Pharmaceuticals 的淨利潤率為 2.23%，股本回報率為 8.20%。該公司本季度的收入為 1.9991 億美元，而分析師預期為 1.9928 億美元。在去年同期，該公司每股收益為（-0.29 美元）。該公司的季度收入同比下降了 5.9%。分析師平均預測 Apellis Pharmaceuticals, Inc.在本年度將發佈-1.23 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Apellis Pharmaceuticals 的看法</h2>
</div><p>Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC grew its holdings in shares of Apellis Pharmaceuticals by 35.9% during the fourth quarter. SG Americas Securities LLC now owns 567,046 shares of the company's stock valued at $14,244,000 after buying an additional 149,654 shares during the last quarter. EFG Asset Management North America Corp. grew its holdings in shares of Apellis Pharmaceuticals by 48.0% during the third quarter. EFG Asset Management North America Corp. now owns 155,399 shares of the company's stock valued at $3,517,000 after buying an additional 50,375 shares during the last quarter. HighVista Strategies LLC grew its holdings in shares of Apellis Pharmaceuticals by 68.2% during the third quarter. HighVista Strategies LLC now owns 145,729 shares of the company's stock valued at $3,298,000 after buying an additional 59,066 shares during the last quarter. Readystate Asset Management LP purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at $5,476,000. Finally, Bank of Nova Scotia grew its holdings in shares of Apellis Pharmaceuticals by 144.8% during the third quarter. Bank of Nova Scotia now owns 1,456,225 shares of the company's stock valued at $32,954,000 after buying an additional 861,413 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近對該股的持倉進行了調整。SG Americas Securities LLC 在第四季度將其在 Apellis Pharmaceuticals 的持倉增加了 35.9%。SG Americas Securities LLC 現在擁有 567,046 股該公司的股票，價值 14,244,000 美元，在上個季度購買了 149,654 股。EFG Asset Management North America Corp.在第三季度將其在 Apellis Pharmaceuticals 的持倉增加了 48.0%。EFG Asset Management North America Corp.現在擁有 155,399 股該公司的股票，價值 3,517,000 美元，在上個季度購買了 50,375 股。HighVista Strategies LLC 在第三季度將其在 Apellis Pharmaceuticals 的持倉增加了 68.2%。HighVista Strategies LLC 現在擁有 145,729 股該公司的股票，價值 3,298,000 美元，在上個季度購買了 59,066 股。Readystate Asset Management LP 在第三季度購買了 Apellis Pharmaceuticals 的新股份，價值 5,476,000 美元。最後，諾瓦斯科舍銀行在第三季度將其在 Apellis Pharmaceuticals 的持倉增加了 144.8%。諾瓦斯科舍銀行現在擁有 1,456,225 股該公司的股票，價值 32,954,000 美元，在上個季度購買了 861,413 股。96.29% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.，在 NASDAQ 交易，股票代碼為 APLS，是一家臨牀階段的生物製藥公司，專注於開發針對補體級聯反應的新療法，以治療罕見且嚴重的疾病。該公司的研發工作集中在調節補體蛋白，以應對一系列眼科、血液和腎臟疾病。Apellis 利用其專有的 compstatin 技術平台設計針對性抑制劑，旨在改善患者的治療效果和生活質量。</p>
</div><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p>
<div class="lb-trans"><p>該公司的主要上市產品 Syfovre（pegcetacoplan）是一種用於治療與年齡相關的黃斑變性引起的地理萎縮的玻璃體內補體 C3 抑制劑，並正在對其他視網膜疾病進行持續研究。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Apellis Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Apellis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Apellis Pharmaceuticals 並不在名單上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Apellis Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week High  - Here's What Happened

Market Beat

Apellis Pharma

基因改革 ETF - ARK

醫療業 ETF - SPDR

生物科技 ETF - VanEck Vectors

醫療業 ETF - Vanguard

動態生物技術與基因組 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

美國制藥 ETF - iShares

標普生物技術 3 倍做多 - Direxion

Beam Therapeutics

花旗

Bank of Nova Scottia

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Apellis Pharmaceuticals（納斯達克代碼：APLS）創下新的 52 周高點 - 事情經過如下